. The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD. Alzheimers Dement (N Y). 2024;10(1):e12446. Epub 2024 Jan 24 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. AGB101